Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis.
Artru F, Bou Saleh M, Maggiotto F, Lassailly G, Ningarhari M, Demaret J, Ntandja-Wandji LC, Pais de Barros JP, Labreuche J, Drumez E, Helou DG, Dharancy S, Gantier E, Périanin A, Chollet-Martin S, Bataller R, Mathurin P, Dubuquoy L, Louvet A. Artru F, et al. J Hepatol. 2020 Jun;72(6):1052-1061. doi: 10.1016/j.jhep.2019.12.017. Epub 2020 Jan 15. J Hepatol. 2020. PMID: 31953139 Free article.
Erratum to: "IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis".
Artru F, Bou Saleh M, Maggiotto F, Lassailly G, Ningarhari M, Demaret J, Ntandja-Wandji LC, Pais de Barros JP, Labreuche J, Drumez E, Helou DG, Dharancy S, Gantier E, Périanin A, Chollet-Martin S, Bataller R, Mathurin P, Dubuquoy L, Louvet A. Artru F, et al. J Hepatol. 2021 May;74(5):1272-1273. doi: 10.1016/j.jhep.2021.02.016. Epub 2021 Mar 11. J Hepatol. 2021. PMID: 33715895 No abstract available.
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R. Corpechot C, et al. N Engl J Med. 2018 Jun 7;378(23):2171-2181. doi: 10.1056/NEJMoa1714519. N Engl J Med. 2018. PMID: 29874528 Free article. Clinical Trial.
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.
Quistrebert J, Hässler S, Bachelet D, Mbogning C, Musters A, Tak PP, Wijbrandts CA, Herenius M, Bergstra SA, Akdemir G, Johannesson M, Combe B, Fautrel B, Chollet-Martin S, Gleizes A, Donnellan N, Deisenhammer F, Davidson J, Hincelin-Mery A, Dönnes P, Fogdell-Hahn A, De Vries N, Huizinga T, Abugessaisa I, Saevarsdottir S, Hacein-Bey-Abina S, Pallardy M, Broët P, Mariette X; ABIRISK Consortium. Quistrebert J, et al. Semin Arthritis Rheum. 2019 Jun;48(6):967-975. doi: 10.1016/j.semarthrit.2018.10.006. Epub 2018 Oct 12. Semin Arthritis Rheum. 2019. PMID: 30420245
181 results